ReNerve kicks off IPO roadshow, points to market darling Orthocell

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 90%

Business News News

Business Business Latest News,Business Business Headlines

ReNerve reckons its NervAlign Nerve Cuff is a lower cost, more effective and easier to use treatment for Peripheral Nerve Injury (PNI).

ASX aspirant ReNerve, which this week launched an investor roadshow to market its initial public offering, is hoping to mirror the success of the only other life-sciences stock on the local bourse.

The nerve-repair company plans to list in late November on the back of an approved product in the United States market. Lead manager Alpine Capital is seeking to raise as much as $7 million for an enterprise value of $20.3 million, according to a prospectus lodged with the corporate regulator.has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in BUSİNESS

Business Business Latest News, Business Business Headlines